Review





Similar Products

96
ATCC human embryonic kidney hek293 cells
MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to <t>HEK293</t> culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = <t>human</t> <t>embryonic</t> <t>kidney;</t> miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.
Human Embryonic Kidney Hek293 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek293+cells/Human+embryonic+kidney+cells%2C+293-hY2-10/pmc12811471-83-0-8
Average 96 stars, based on 1 article reviews
human embryonic kidney hek293 cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
ATCC virus packaging cell line hek293
MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to <t>HEK293</t> culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = <t>human</t> <t>embryonic</t> <t>kidney;</t> miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.
Virus Packaging Cell Line Hek293, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek293+cells/293/pmc13756994-42-27-36
Average 99 stars, based on 1 article reviews
virus packaging cell line hek293 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC hek293 cells
(A) Schematic diagram of the PI3P metabolic pathway, where class III PI3K is responsible for the generation of PI3P from PI and PIKfyve is for the generation of PI(3,5)P 2 from PI3P. Compounds that inhibit each kinase are also shown. (B) Immunostaining of intracellular vacuoles formed by treatment with apilimod (Api) or YM201636 (YM) in RAW264.7 cells. Vacuoles were stained with anti-LAMP1 antibody (red), and nuclei were stained with DAPI (cyan). Scale bar = 10 μm. (C, D, E, F) Immunoblot analysis of Thr73-phosphorylated Rab10 (pRab10) and other indicated proteins in RAW264.7 cells treated with PIKfyve inhibitors, as well as VPS34-IN1 (C, D) or Cmpd19 (E, F). Bar graphs in (D, F) show quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 6 (D) or 3 (F), and the difference was analyzed using two-way ANOVA with Tukey’s test. (G, H) Immunoblot analysis of pRab10 and other proteins in A549 cells treated with PIKfyve inhibitors, as well as VPS34-IN1. A bar graph in (H) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (I, J) Immunoblot analysis of pRab10 in <t>HEK293</t> cells that overexpress GFP, LRRK2 WT, or pathogenic mutants (R1441C, Y1699C) and are treated with PIKfyve inhibitors. A bar graph in (J) shows quantification of pRab10/total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (K) Schematic illustration of the activation induction mechanism of PI3K by Tat-D11. (L, M) Immunoblot analysis of pRab10 and other indicated proteins upon treatment with Tat-D11 and/or Cmpd19 in RAW264.7 cells. A bar graph in (M) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. Cmpd19, Compound 19. Source data are available for this figure.
Hek293 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek293+cells/293/pmc13743929-194-0-2
Average 99 stars, based on 1 article reviews
hek293 cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

cells  (ATCC)
99
ATCC cells
(A) Schematic diagram of the PI3P metabolic pathway, where class III PI3K is responsible for the generation of PI3P from PI and PIKfyve is for the generation of PI(3,5)P 2 from PI3P. Compounds that inhibit each kinase are also shown. (B) Immunostaining of intracellular vacuoles formed by treatment with apilimod (Api) or YM201636 (YM) in RAW264.7 cells. Vacuoles were stained with anti-LAMP1 antibody (red), and nuclei were stained with DAPI (cyan). Scale bar = 10 μm. (C, D, E, F) Immunoblot analysis of Thr73-phosphorylated Rab10 (pRab10) and other indicated proteins in RAW264.7 cells treated with PIKfyve inhibitors, as well as VPS34-IN1 (C, D) or Cmpd19 (E, F). Bar graphs in (D, F) show quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 6 (D) or 3 (F), and the difference was analyzed using two-way ANOVA with Tukey’s test. (G, H) Immunoblot analysis of pRab10 and other proteins in A549 cells treated with PIKfyve inhibitors, as well as VPS34-IN1. A bar graph in (H) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (I, J) Immunoblot analysis of pRab10 in <t>HEK293</t> cells that overexpress GFP, LRRK2 WT, or pathogenic mutants (R1441C, Y1699C) and are treated with PIKfyve inhibitors. A bar graph in (J) shows quantification of pRab10/total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (K) Schematic illustration of the activation induction mechanism of PI3K by Tat-D11. (L, M) Immunoblot analysis of pRab10 and other indicated proteins upon treatment with Tat-D11 and/or Cmpd19 in RAW264.7 cells. A bar graph in (M) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. Cmpd19, Compound 19. Source data are available for this figure.
Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek293+cells/HEK293S+GnTI/10__1113_slash_jp287479-127-19-21
Average 99 stars, based on 1 article reviews
cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney 293 hek293 cells
(A) Schematic diagram of the PI3P metabolic pathway, where class III PI3K is responsible for the generation of PI3P from PI and PIKfyve is for the generation of PI(3,5)P 2 from PI3P. Compounds that inhibit each kinase are also shown. (B) Immunostaining of intracellular vacuoles formed by treatment with apilimod (Api) or YM201636 (YM) in RAW264.7 cells. Vacuoles were stained with anti-LAMP1 antibody (red), and nuclei were stained with DAPI (cyan). Scale bar = 10 μm. (C, D, E, F) Immunoblot analysis of Thr73-phosphorylated Rab10 (pRab10) and other indicated proteins in RAW264.7 cells treated with PIKfyve inhibitors, as well as VPS34-IN1 (C, D) or Cmpd19 (E, F). Bar graphs in (D, F) show quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 6 (D) or 3 (F), and the difference was analyzed using two-way ANOVA with Tukey’s test. (G, H) Immunoblot analysis of pRab10 and other proteins in A549 cells treated with PIKfyve inhibitors, as well as VPS34-IN1. A bar graph in (H) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (I, J) Immunoblot analysis of pRab10 in <t>HEK293</t> cells that overexpress GFP, LRRK2 WT, or pathogenic mutants (R1441C, Y1699C) and are treated with PIKfyve inhibitors. A bar graph in (J) shows quantification of pRab10/total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (K) Schematic illustration of the activation induction mechanism of PI3K by Tat-D11. (L, M) Immunoblot analysis of pRab10 and other indicated proteins upon treatment with Tat-D11 and/or Cmpd19 in RAW264.7 cells. A bar graph in (M) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. Cmpd19, Compound 19. Source data are available for this figure.
Human Embryonic Kidney 293 Hek293 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek293+cells/293/pm42986964-560-0-6
Average 99 stars, based on 1 article reviews
human embryonic kidney 293 hek293 cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC human embryonic kidney cell line hek293
(A) Schematic diagram of the PI3P metabolic pathway, where class III PI3K is responsible for the generation of PI3P from PI and PIKfyve is for the generation of PI(3,5)P 2 from PI3P. Compounds that inhibit each kinase are also shown. (B) Immunostaining of intracellular vacuoles formed by treatment with apilimod (Api) or YM201636 (YM) in RAW264.7 cells. Vacuoles were stained with anti-LAMP1 antibody (red), and nuclei were stained with DAPI (cyan). Scale bar = 10 μm. (C, D, E, F) Immunoblot analysis of Thr73-phosphorylated Rab10 (pRab10) and other indicated proteins in RAW264.7 cells treated with PIKfyve inhibitors, as well as VPS34-IN1 (C, D) or Cmpd19 (E, F). Bar graphs in (D, F) show quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 6 (D) or 3 (F), and the difference was analyzed using two-way ANOVA with Tukey’s test. (G, H) Immunoblot analysis of pRab10 and other proteins in A549 cells treated with PIKfyve inhibitors, as well as VPS34-IN1. A bar graph in (H) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (I, J) Immunoblot analysis of pRab10 in <t>HEK293</t> cells that overexpress GFP, LRRK2 WT, or pathogenic mutants (R1441C, Y1699C) and are treated with PIKfyve inhibitors. A bar graph in (J) shows quantification of pRab10/total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (K) Schematic illustration of the activation induction mechanism of PI3K by Tat-D11. (L, M) Immunoblot analysis of pRab10 and other indicated proteins upon treatment with Tat-D11 and/or Cmpd19 in RAW264.7 cells. A bar graph in (M) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. Cmpd19, Compound 19. Source data are available for this figure.
Human Embryonic Kidney Cell Line Hek293, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek293+cells/293/pm42982199-43-20-30
Average 99 stars, based on 1 article reviews
human embryonic kidney cell line hek293 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
ATCC adherent hek293 cells
(A) Schematic diagram of the PI3P metabolic pathway, where class III PI3K is responsible for the generation of PI3P from PI and PIKfyve is for the generation of PI(3,5)P 2 from PI3P. Compounds that inhibit each kinase are also shown. (B) Immunostaining of intracellular vacuoles formed by treatment with apilimod (Api) or YM201636 (YM) in RAW264.7 cells. Vacuoles were stained with anti-LAMP1 antibody (red), and nuclei were stained with DAPI (cyan). Scale bar = 10 μm. (C, D, E, F) Immunoblot analysis of Thr73-phosphorylated Rab10 (pRab10) and other indicated proteins in RAW264.7 cells treated with PIKfyve inhibitors, as well as VPS34-IN1 (C, D) or Cmpd19 (E, F). Bar graphs in (D, F) show quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 6 (D) or 3 (F), and the difference was analyzed using two-way ANOVA with Tukey’s test. (G, H) Immunoblot analysis of pRab10 and other proteins in A549 cells treated with PIKfyve inhibitors, as well as VPS34-IN1. A bar graph in (H) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (I, J) Immunoblot analysis of pRab10 in <t>HEK293</t> cells that overexpress GFP, LRRK2 WT, or pathogenic mutants (R1441C, Y1699C) and are treated with PIKfyve inhibitors. A bar graph in (J) shows quantification of pRab10/total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (K) Schematic illustration of the activation induction mechanism of PI3K by Tat-D11. (L, M) Immunoblot analysis of pRab10 and other indicated proteins upon treatment with Tat-D11 and/or Cmpd19 in RAW264.7 cells. A bar graph in (M) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. Cmpd19, Compound 19. Source data are available for this figure.
Adherent Hek293 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hek293+cells/293/pm42983944-125-0-3
Average 99 stars, based on 1 article reviews
adherent hek293 cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to HEK293 culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = human embryonic kidney; miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.

Journal: Journal of Sport and Health Science

Article Title: Exercise training-induced extracellular miR-136-3p modulates glucose uptake and myogenesis through targeting of NRDC in human skeletal muscle

doi: 10.1016/j.jshs.2025.101091

Figure Lengend Snippet: MiR-136-3p content in cell culture medium and uptake of extracellular miR-136-3p into cultured myotubes. MiRNA content in (A) human myotubes and (B) human pancreatic islets culture media. Results were first normalized using RNU1A1 and then presented in relation to miR-23a-3p content for n = 4 different donors for myotubes cultures and n = 4 donors for human islets. Left panel (C) shows bright-field image of cultured human myotubes and right panel (C) shows a representative fluorescence image of cultured human myotubes with cells exposed to human serum-derived EVs loaded with Cy3-miR-136-3p. Cy3 fluorescence (red) is detected in the whole cytoplasm of the human myotubes. (D) Representative fluorescence image of human myotubes exposed to HEK293 culture medium with EVs loaded with Cy3-miR-136-3p (red). (E) Representative image of human myotubes exposed to EVs loaded with TexasRed-labeled with a control RNA (orange). Nuclear Hoechst staining is shown in blue. Scale bar = 100 μm. EVs = extracellular vesicles; HEK293 = human embryonic kidney; miR = microRNA; Rel = relative; RNU1A1 = U1 small nuclear RNA.

Article Snippet: Human embryonic kidney (HEK293) cells were obtained from American Type Culture Collection (ATCC) and cultured in high-glucose (4.5 g/L) Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% (vol/vol) FBS.

Techniques: Cell Culture, Fluorescence, Derivative Assay, Labeling, Control, Staining

NRDC is a direct target of miR-136-3p in human myotubes. Skeletal muscle NRDC mRNA is responsive to training and inactivity. (A) Tissue mRNA expression of NRDC from the Human Protein Atlas database showing enriched expression of NRDC in human skeletal muscle. (B) The miR-136-3p target site in the NRDC gene is highly conserved in mammals. (C) Luciferase activity in HEK293 cells co-transfected the NRDC 3’UTR and miR-136-3p with or without anti-miR136-3p inhibitors. miR-136-3p transfection downregulates NRDC (D) mRNA and (E) representative image of protein abundance in human myotubes. (F) Publicly available data ( GSE14413 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 6 weeks of endurance training ( n = 8). (G) Publicly available data ( GSE120862 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 2 months of aerobic training ( n = 10). (H) Publicly available data ( GSE14901 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 14 days of immobilization ( n = 24). * p < 0.05, ** p < 0.005. GSE = gene set enrichment; HEK293 = human embryonic kidney; miR = microRNA; NC = negative control; NRDC = nardilysin convertase; nTPM = normalized transcripts per million; si NRDC = small interfering RNA of NRDC ; UTR = untranslated region.

Journal: Journal of Sport and Health Science

Article Title: Exercise training-induced extracellular miR-136-3p modulates glucose uptake and myogenesis through targeting of NRDC in human skeletal muscle

doi: 10.1016/j.jshs.2025.101091

Figure Lengend Snippet: NRDC is a direct target of miR-136-3p in human myotubes. Skeletal muscle NRDC mRNA is responsive to training and inactivity. (A) Tissue mRNA expression of NRDC from the Human Protein Atlas database showing enriched expression of NRDC in human skeletal muscle. (B) The miR-136-3p target site in the NRDC gene is highly conserved in mammals. (C) Luciferase activity in HEK293 cells co-transfected the NRDC 3’UTR and miR-136-3p with or without anti-miR136-3p inhibitors. miR-136-3p transfection downregulates NRDC (D) mRNA and (E) representative image of protein abundance in human myotubes. (F) Publicly available data ( GSE14413 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 6 weeks of endurance training ( n = 8). (G) Publicly available data ( GSE120862 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 2 months of aerobic training ( n = 10). (H) Publicly available data ( GSE14901 ) showing NRDC mRNA expression in human skeletal muscle of healthy young participants after 14 days of immobilization ( n = 24). * p < 0.05, ** p < 0.005. GSE = gene set enrichment; HEK293 = human embryonic kidney; miR = microRNA; NC = negative control; NRDC = nardilysin convertase; nTPM = normalized transcripts per million; si NRDC = small interfering RNA of NRDC ; UTR = untranslated region.

Article Snippet: Human embryonic kidney (HEK293) cells were obtained from American Type Culture Collection (ATCC) and cultured in high-glucose (4.5 g/L) Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% (vol/vol) FBS.

Techniques: Expressing, Luciferase, Activity Assay, Transfection, Quantitative Proteomics, Negative Control, Small Interfering RNA

(A) Schematic diagram of the PI3P metabolic pathway, where class III PI3K is responsible for the generation of PI3P from PI and PIKfyve is for the generation of PI(3,5)P 2 from PI3P. Compounds that inhibit each kinase are also shown. (B) Immunostaining of intracellular vacuoles formed by treatment with apilimod (Api) or YM201636 (YM) in RAW264.7 cells. Vacuoles were stained with anti-LAMP1 antibody (red), and nuclei were stained with DAPI (cyan). Scale bar = 10 μm. (C, D, E, F) Immunoblot analysis of Thr73-phosphorylated Rab10 (pRab10) and other indicated proteins in RAW264.7 cells treated with PIKfyve inhibitors, as well as VPS34-IN1 (C, D) or Cmpd19 (E, F). Bar graphs in (D, F) show quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 6 (D) or 3 (F), and the difference was analyzed using two-way ANOVA with Tukey’s test. (G, H) Immunoblot analysis of pRab10 and other proteins in A549 cells treated with PIKfyve inhibitors, as well as VPS34-IN1. A bar graph in (H) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (I, J) Immunoblot analysis of pRab10 in HEK293 cells that overexpress GFP, LRRK2 WT, or pathogenic mutants (R1441C, Y1699C) and are treated with PIKfyve inhibitors. A bar graph in (J) shows quantification of pRab10/total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (K) Schematic illustration of the activation induction mechanism of PI3K by Tat-D11. (L, M) Immunoblot analysis of pRab10 and other indicated proteins upon treatment with Tat-D11 and/or Cmpd19 in RAW264.7 cells. A bar graph in (M) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. Cmpd19, Compound 19. Source data are available for this figure.

Journal: Life Science Alliance

Article Title: PIKfyve inhibition induces LRRK2 activation through phosphatidylinositol 3-phosphate and CASM

doi: 10.26508/lsa.202603939

Figure Lengend Snippet: (A) Schematic diagram of the PI3P metabolic pathway, where class III PI3K is responsible for the generation of PI3P from PI and PIKfyve is for the generation of PI(3,5)P 2 from PI3P. Compounds that inhibit each kinase are also shown. (B) Immunostaining of intracellular vacuoles formed by treatment with apilimod (Api) or YM201636 (YM) in RAW264.7 cells. Vacuoles were stained with anti-LAMP1 antibody (red), and nuclei were stained with DAPI (cyan). Scale bar = 10 μm. (C, D, E, F) Immunoblot analysis of Thr73-phosphorylated Rab10 (pRab10) and other indicated proteins in RAW264.7 cells treated with PIKfyve inhibitors, as well as VPS34-IN1 (C, D) or Cmpd19 (E, F). Bar graphs in (D, F) show quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 6 (D) or 3 (F), and the difference was analyzed using two-way ANOVA with Tukey’s test. (G, H) Immunoblot analysis of pRab10 and other proteins in A549 cells treated with PIKfyve inhibitors, as well as VPS34-IN1. A bar graph in (H) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (I, J) Immunoblot analysis of pRab10 in HEK293 cells that overexpress GFP, LRRK2 WT, or pathogenic mutants (R1441C, Y1699C) and are treated with PIKfyve inhibitors. A bar graph in (J) shows quantification of pRab10/total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (K) Schematic illustration of the activation induction mechanism of PI3K by Tat-D11. (L, M) Immunoblot analysis of pRab10 and other indicated proteins upon treatment with Tat-D11 and/or Cmpd19 in RAW264.7 cells. A bar graph in (M) shows quantification of pRab10 relative to total Rab10. Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. Cmpd19, Compound 19. Source data are available for this figure.

Article Snippet: HEK293 cells (ATCC, RRID: CVCL_0045) and human lung carcinoma A549 cells (ECACC, RRID: CVCL_0023) were cultured on normal dishes in DMEM supplemented with 10% (vol/vol) FBS.

Techniques: Immunostaining, Staining, Western Blot, Analysis, Activation Assay

(A) Protein–lipid overlay assays for the detection of the interaction of full-length (left) or N-terminally truncated (970-2527aa, right) LRRK2 with various PIPs. The names of phospholipids corresponding to each spot are shown on the right. Representative pictures from three independent experiments are shown. (B, C) Liposome pull-down assay for the detection of the interaction of full-length LRRK2 with biotin-conjugated liposomes containing PI, PI3P, or PI(3,5)P 2 . LRRK2 bands in the flow-through (FT) and bound fractions are shown. A dot plot in (C) shows quantification of LRRK2 in the bound fraction, as shown in B. n = 4, one-way ANOVA with Tukey’s test. (D) Structure of the positively charged cluster in the N-terminal region of LRRK2, predicted to interact with PI3P. Side chains of candidate residues predicted to face the membrane are indicated by red arrows. (E) Analysis of apilimod-induced activation of mutant LRRK2 harboring alanine substitutions for the N-terminal positively charged amino acids in HEK293 cells. (F) Quantitative analysis of Thr73-phosphorylated Rab10 relative to total Rab10, as shown in (C). Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (G) Protein–lipid overlay assays for the detection of interaction of WT LRRK2 (left) or PentaA LRRK2 (right) with PIPs. The arrangement of phospholipids is the same as that shown in (A). Representative pictures from three independent experiments are shown. (H) Model of LRRK2 activation via PI3P, multiple Rabs, and CASM effector GABARAP on membranes. The N-terminal region of LRRK2 functions as a hotspot of interaction with these molecules, mediating LRRK2 activation. aa, amino acids. Source data are available for this figure.

Journal: Life Science Alliance

Article Title: PIKfyve inhibition induces LRRK2 activation through phosphatidylinositol 3-phosphate and CASM

doi: 10.26508/lsa.202603939

Figure Lengend Snippet: (A) Protein–lipid overlay assays for the detection of the interaction of full-length (left) or N-terminally truncated (970-2527aa, right) LRRK2 with various PIPs. The names of phospholipids corresponding to each spot are shown on the right. Representative pictures from three independent experiments are shown. (B, C) Liposome pull-down assay for the detection of the interaction of full-length LRRK2 with biotin-conjugated liposomes containing PI, PI3P, or PI(3,5)P 2 . LRRK2 bands in the flow-through (FT) and bound fractions are shown. A dot plot in (C) shows quantification of LRRK2 in the bound fraction, as shown in B. n = 4, one-way ANOVA with Tukey’s test. (D) Structure of the positively charged cluster in the N-terminal region of LRRK2, predicted to interact with PI3P. Side chains of candidate residues predicted to face the membrane are indicated by red arrows. (E) Analysis of apilimod-induced activation of mutant LRRK2 harboring alanine substitutions for the N-terminal positively charged amino acids in HEK293 cells. (F) Quantitative analysis of Thr73-phosphorylated Rab10 relative to total Rab10, as shown in (C). Data represent the mean ± SEM, n = 4, two-way ANOVA with Tukey’s test. (G) Protein–lipid overlay assays for the detection of interaction of WT LRRK2 (left) or PentaA LRRK2 (right) with PIPs. The arrangement of phospholipids is the same as that shown in (A). Representative pictures from three independent experiments are shown. (H) Model of LRRK2 activation via PI3P, multiple Rabs, and CASM effector GABARAP on membranes. The N-terminal region of LRRK2 functions as a hotspot of interaction with these molecules, mediating LRRK2 activation. aa, amino acids. Source data are available for this figure.

Article Snippet: HEK293 cells (ATCC, RRID: CVCL_0045) and human lung carcinoma A549 cells (ECACC, RRID: CVCL_0023) were cultured on normal dishes in DMEM supplemented with 10% (vol/vol) FBS.

Techniques: Pull Down Assay, Liposomes, Membrane, Analysis, Activation Assay, Mutagenesis